Preprocedural C-reactive protein predictive value in angiographic in-stent restenosis after coronary stent placement in patients with stable angina

Archives of Medical Science

Volumn 5, Issue 2, 2009, Pages 166-171

  Khosravi, Alireza ^a   Kelishadi, Roya ^a   Poormoghadas, Massoud ^a   Shirani, Shahin ^a   Asgary, Sedigheh ^a   Khosravi, Mohammadreza ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Baremetal stent; C reactive protein; Diabetes; Restenosis; Stable angina; Stents

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; RIGHT CORONARY ARTERY; SMOKING; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70349675765     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
2. Emanuelsson H, Serruys PW, van Der Giessen WJ, et al. Clinical and angiographic results with the multi-link coronary stent system. The West Europian Stent Trial (WEST). J Invasive Cardiol 1998; 10: 12B-9B.
3. Karaca I, Aydin K, Yavuzkir M, et al. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. J Int Med Res 2005; 33: 389-96.
4. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting humans. Circulation 2002; 105: 2974-80.
5. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998; 82: 515-8.
6. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-6.
7. De Winter RJ, Bhollasingh R, Lijmer JG, et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res 1999; 42: 240-5.
8. Pietilä KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996; 17: 1345-9.
9. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512-21.
10. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839-46.
11. Rittersma SZ, de Winter RJ, Koch KT, et al. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem 2004; 50: 1589-96.
12. Wahlgren CM, Sten-Linder M, Egberg N, Kalin B, Blohme L, Swedenborg J. The role of coagulation and inflammation after angioplasty in patients with peripheral arterial disease. Cardiovasc Intervent Radiol 2006; 29: 530-5.
13. Smith SC Jr, Feldman TE, Hirshfeld J Jr, et al. ACC/AHA/CAI 2005 guiline update for percutaneous coronary intervention: A report of the American Colleege of Cardiology/American Heart asssociation task force on practice guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). J Am Coll Cardiol 2006; 47: e1-121.
14. Mancini GB, Simon SB, McGillen MJ, Lefree MT, Friedman HZ, Vogel RA. Automated quantitative coronary angiography: morphologic and physiologic validation in vivo of a rapid digital angiographic method. Circulation 1987; 75: 452-60.
15. Yip HK, Hung WC, Yang CH, et al. Serum concentrations of high-sensitivity C-reactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery stenting. Circ J 2005; 69: 1202-7.
16. Segev A, Kassam S, Buller CE, et al. Pre-procedural plasma levels of C-reactive protein and interlukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J 2004; 25: 1029-35.
17. Hong YJ, Jeong MH, Lim SY, Lee SR, Hong SN, Kim KH. Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting. Am J Cardiol 2006; 98: 341-5.
18. Dibra A, Mehilli J, Braun S, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003; 114: 715-22.
19. Piek JJ, van der Wal AC, Meuwissen M, et al. Plaque inflammation in restenotic coronary lesions of patients with stable or unstable angina. J Am Coll Cardiol 2000; 35: 963-73.
20. Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 2003; 91: 287-92.
21. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22: 1769-76.
22. Walter DH, Fichtlscherer S, Britten MB, et al. Statin therpy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001; 38: 2006-12.
23. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999; 20: 58-69.
24. Mulder HJ, Bal ET, Jukema JW, et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol 2000; 86: 742-6.
25. Tenda K, Saikawa T, Maeda T, et al. The relationship between serum lipoprotein (a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. Jpn Circ J 1993; 57: 789-95.
26. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91: 1403-9.
27. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation 1994; 90: 2267-79.
28. Foley JB, Younger K, Foley D, et al. Lipids and fatty acids and their relationship to restenosis. Cathet Cardiovasc Diagn 1992; 25: 25-30.
29. Alaigh P, Hoffman CJ, Korlipara G, et al. Lipoprotein (a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arteroscler Thromb Vasc Biol 1998; 18: 1281-6.
30. Heidland UE, Heintzen MP, Michel CJ, Strauer BE. Risk factors for the development of restenosis following stent implantation of venous bypass grafts. Heart 2001; 85: 312-7.
31. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-73.
32. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118: 344-9.
33. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma lipoprotein (a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998; 98: 1172-7.
34. Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96: 1454-60.
35. Bauters C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998; 31: 1291-8.
36. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528-35.
37. Heidland UE, Heintzan MP, Klimek WJ, Michel CJ, Strauer BE. Acute complications and restenosis in women undergoing PTCA. It is possible to define sex. Differences and to determine risk factors? J Cardiovascular Risk 1998; 5: 297-302.
38. Gürlek A, Daǧalp Z, Oral D, et al. Restenosis after transluminal coronary angioplasty: a risk factor analysis. J Cardiovasc Risk 1995; 21: 51-5.
39. Taira DA, Seto TB, Ho KK, et al. Impact of smoking on health-related quality of life after percutaneous coronary revascularization. Circulation 2000; 102: 1369-74.
40. Wong SC, Baim DS, Schatz RA, et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-schatz stent experience. The palmaz-schatz stent group. The Palmaz-Schatz Stent Study Group. J Am Coll Cardiol 1995; 26: 704-12.